Monday, January 30, 2023
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
Daily Remedy
  • Home
  • Articles
  • Podcasts
    A conversation with Dr. Selwyn O. Rogers, trauma surgeon and gun policy expert

    A conversation with Dr. Selwyn O. Rogers, trauma surgeon and gun policy expert

    November 25, 2022
    A conversation with Dr. Kyle Fischer, policy director for the Health Alliance for Violence Intervention

    A conversation with Dr. Kyle Fischer, policy director for the Health Alliance for Violence Intervention

    November 25, 2022
    A conversation with Dr. Edwin Leap, physician writer and emergency medicine physician

    A conversation with Dr. Edwin Leap, writer and emergency medicine physician

    November 8, 2022
    A conversation with Mr. Omar M Khateeb, innovator in medical device sales

    A conversation with Mr. Omar M Khateeb, innovator in medical device sales

    October 31, 2022
    A conversation with Miss Smriti Kirubanandan, passionate healthcare strategist

    A conversation with Miss Smriti Kirubanandan, passionate healthcare strategist

    October 23, 2022
    A conversation with Mr. Michael Johnson, legal expert in physician contracts

    A conversation with Mr. Michael Johnson, legal expert in physician contracts

    October 23, 2022
  • Surveys

    Surveys

    Does inflation affect how you use your deductible?

    Does inflation affect how you use your deductible?

    by Jay K Joshi
    December 12, 2022

    Survey Resutls

    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    October 16, 2022
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    A conversation with Dr. Selwyn O. Rogers, trauma surgeon and gun policy expert

    A conversation with Dr. Selwyn O. Rogers, trauma surgeon and gun policy expert

    November 25, 2022
    A conversation with Dr. Kyle Fischer, policy director for the Health Alliance for Violence Intervention

    A conversation with Dr. Kyle Fischer, policy director for the Health Alliance for Violence Intervention

    November 25, 2022
    A conversation with Dr. Edwin Leap, physician writer and emergency medicine physician

    A conversation with Dr. Edwin Leap, writer and emergency medicine physician

    November 8, 2022
    A conversation with Mr. Omar M Khateeb, innovator in medical device sales

    A conversation with Mr. Omar M Khateeb, innovator in medical device sales

    October 31, 2022
    A conversation with Miss Smriti Kirubanandan, passionate healthcare strategist

    A conversation with Miss Smriti Kirubanandan, passionate healthcare strategist

    October 23, 2022
    A conversation with Mr. Michael Johnson, legal expert in physician contracts

    A conversation with Mr. Michael Johnson, legal expert in physician contracts

    October 23, 2022
  • Surveys

    Surveys

    Does inflation affect how you use your deductible?

    Does inflation affect how you use your deductible?

    by Jay K Joshi
    December 12, 2022

    Survey Resutls

    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    October 16, 2022
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Innovations & Investing

Startup Innovation Meets DOJ Regulations

Jay K Joshi by Jay K Joshi
May 15, 2022
in Innovations & Investing
0
Startup Innovation Meets DOJ Regulations

Healthcare innovation has a unique relationship with federal regulation. Like a veritable cat and mouse game, the Department of Justice (DOJ) is constantly chasing after healthcare startups that push the envelope just a little too aggressively.

In recent months, there have been two notable investigations. The first was against startup Oak Street Health, a value-based primary care network for Medicare patients. The chain of primary care clinics faced a DOJ inquiry into its relationships with third-party marketing agents and its provision of free transportation for members. The second is more recent, against a mental health startup Cerebral, over its prescribing of controlled substances like Adderall and Xanax through telemedicine.

At first blush, the two investigations may appear different. But they belie a common investigational tactic used by the DOJ – target the patient recruitment methods of a healthcare company and determine whether these methods constitute illegal marketing tactics. It is a remarkable strategy because it puts healthcare companies at a uniquely disadvantageous position and gives federal prosecutors a tremendous – and possibly undue – advantage.

Marketing in healthcare has always been murky. And of late, the line between representing medical data and influencing public perception has blurred into an interpretive oblivion. Where marketing begins and ends is anyone’s guess. The DOJ capitalizes on this ambiguity to elicit the pretense of criminality, or at least of impropriety, in what otherwise would be established medical practice.

Pharmaceutical representatives have been coming into physician offices for years to discuss new medications and its benefits. It has been acknowledged that conflicts of interest can occur through such relationships, but provisions were set in place to minimize them. But regardless of what safeguards are placed, we will always have some gray area where pharmaceutical companies can leverage influence.

It happens at all levels of healthcare. Pfizer and Moderna actively collaborated with the FDA to demonstrate the clinical utility of a fourth COVID-19 vaccine dose. Yet the cries calling for a conflict of interest investigation in this arrangement rang hollow. It would be both naïve and insincere to suggest that neither company is profiting off their status as saviors of the pandemic. Just look at Pfizer’s 2021 annual shareholders report.

This is the point of contention for many healthcare startups who feel unduly targeted for their marketing efforts. There is no consistent standard by which healthcare companies are evaluated for inappropriate recruitment methods.

We have no set parameters to determine whether a Medicare Advantage company subsidizing car rides to incentivize patient visits constitutes good quality of care or illegal marketing tactics. It is subjective, and that is the problem.

When the interpretation of law is subject to the interpretations of those enforcing it, then those most vulnerable to the law are disproportionately affected by malicious interpretations. In healthcare, these would be the healthcare startups. The fledgling companies who seek to improve healthcare by taking genuine risks.

To re-contextualize those risks as crimes is anathema to the American spirit of ingenuity. Yet it is precisely the tactic taken by the DOJ. This is nothing short of disingenuous by the DOJ.

Look no further than the misguided attempt to introduce price transparency into healthcare. Former Center for Medicare and Medicaid Director, Seema Verma, wrote an op-ed comparing price transparency in healthcare to buying a car – as though the experiences are similar.

But the Government Accountability Office (GAO) has long acknowledged that price transparency is uniquely difficult in healthcare.

It is time the DOJ develop unique investigational practices specific to healthcare that recognize the unique patient experience. In other industries, a customer is a consumer, subject to laws of consumer behavior and general commerce. But in healthcare, we have patients, not consumers.

Needless to say, a patient is distinct from a consumer. And the distinctions merit different methods of regulating general business practices in healthcare. We would not consider theft to be the same as murder. We separate different crimes with their own punishments, unique to each criminal behavior.

When we muddle these distinctions, we create laws that make crimes out of behavior that would be standard industry practice. This is the current cat and mouse game between the DOJ and healthcare startups, balancing the line between marketing as a vehicle for growth and marketing as a criminal act.

ShareTweet
Jay K Joshi

Jay K Joshi

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

YouTube Video VVUxUDVQenU5RTFjUVFKNDY2ZlBmdFB3LmdVUm55WVpqRmNn This is a video about Elemental/Essential Frameworks of Healthcare Law

00:00 Elemental/Essential Frameworks of Healthcare Law
Load More... Subscribe

Expert vs. Lay Testimony

Visuals

NADAC (National Average Drug Acquisition Cost)

NADAC (National Average Drug Acquisition Cost)

by Jay K Joshi
January 29, 2023
0

We list the acquisition price of drugs that are covered under the Medicaid Drug Rebate Program - effectively, how much does the government pay for common drugs utilized by patients on Medicaid. Drugs listed are from A-CH.  

Read more

Twitter Updates

Tweets by DailyRemedy1

Newsletter

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do

Popular

  • Letter to the Alabama Board of Medical Examiners

    Letter to the Alabama Board of Medical Examiners

    0 shares
    Share 0 Tweet 0
  • Prosecuting Doctors as Drug Dealers

    0 shares
    Share 0 Tweet 0
  • Malicious Prosecution and Fabrication of Evidence

    0 shares
    Share 0 Tweet 0
  • Why Our Prescribing were for Patients’ Best Interests

    0 shares
    Share 0 Tweet 0
  • My Respect for the Law

    0 shares
    Share 0 Tweet 0

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Newsletter

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2023 Daily Remedy

No Result
View All Result
  • Home
  • Articles
    • Contrarian
    • Financial Markets
    • Innovations & Investing
    • Perspectives
    • Politics & Law
    • Trends
    • Uncertainty & Complexity
  • Podcasts
  • Surveys
    • Survey Results
  • About Us
  • Contact us
  • Support Us

© 2023 Daily Remedy

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do